Subcutaneous Ocrelizumab Funded for Multiple Sclerosis
Pharmac have, today, announced they will fund subcutaneous ocrelizumab for multiple sclerosis. Multiple Sclerosis NZ and the wider MS community warmly welcome this landmark decision, bringing renewed hope to the lives of those affected by MS. We hope this decision is the first of many in improving patient experiences, access to treatments and system improvements. […]
Ocrelizumab Subcut Receives Medsafe Registration as Pressure Mounts to Fund Wider Range of MS Treatment Options
Photo by Kristine Wook, Unsplash. Medsafe have approved the registration of Ocrevus ® Subcutaneous (SC) (ocrelizumab and hyaluronidase) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS). The announcement on 24th April is welcomed by Multiple Sclerosis New Zealand. “The registration of Ocrevus SC is […]
Media Release: New report calls for major change to Pharmac’s funding model
Pharmac’s decision-making process for funding drugs in Aotearoa New Zealand is in need of a major overhaul – according to a new independent report. The Milne Report, commissioned by Multiple Sclerosis New Zealand (MSNZ), says its time Pharmac based its funding decisions not just on the cost of a drug or medical device, but on […]
Major announcement: Pharmac Initiates Consultation to fund Ocrelizumab for Primary Progressive MS.
Multiple Sclerosis New Zealand (MSNZ) is delighted to share that Pharmac have commenced consultation to fund Ocrelizumab for Primary Progressive MS. Currently, those with PPMS have no access to any disease modifying therapies. Ocrelizumab has been proven in trials to delay time to wheelchair by 7 years allowing people to continue working, supporting their families […]
Covid-19 in Ocrelizumab-treated people with Multiple Sclerosis
This article, written by the Journal of Multiple Sclerosis and related disorders, (MSARD) includes data from clinical trials, post marketing safety surveillance and a US electronic medical records database, Optum. The objective was to better understand the SARS-CoV-2 infection in ocrelizumab-treated people with MS. The results show: Roche/Genentech clinical trial data: There were 51 (1.3%) […]